Latest news with #prostatecancer
Yahoo
6 hours ago
- Business
- Yahoo
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. 'Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,' said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. 'We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.' About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie Fields Precision AQ (Formerly Stern IR) E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – Twitter – Linked In – –
Telegraph
6 hours ago
- Health
- Telegraph
The new stage four cancer treatments and what they mean for patients
A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden's prostate cancer was recently labelled 'aggressive' and described as having spread to his bones, many assumed the worst. Yet today, thanks to astonishing advances in cancer science, a stage-four label need not mean imminent death. 'Stage four means the cancer has spread to another part of the body further away from where it started,' explains Dr Ben O'Leary, a clinical oncologist at the Royal Marsden and a researcher at The Institute of Cancer Research (ICR). 'Most stage-four cancers still can't be cured, but our deeper understanding of how cancers evolve and grow means many people are living longer. In some cases, we now see responses, and yes, even cures, that weren't thought possible 10 years ago.' What's driving this optimism? Five types of cancer offer a snapshot of progress. Skip to: Prostate cancer Blood cancers Breast cancer Bladder cancer Lung cancer Prostate cancer By the age of 80, half of men harbour cancer in their prostate, though it proves fatal in only a small minority. Even so, around 12,000 men die of metastatic prostate cancer each year in the UK. Dr Anna Wilkins of the ICR and Royal Marsden says metastatic prostate cancer most often spreads to the bones. 'On scans, you can see up to 50 spots all over the skeleton. But there has been big progress in new drugs.' Total testosterone blockade Standard treatment reduces testosterone, the hormone that fuels tumour growth. Abiraterone, developed at the ICR, goes further by blocking its precursor hormones, extending survival significantly. Liquid radiotherapy This exciting development involves injecting patients with a radioactive liquid. Cancer cells 'drink' more of the liquid than healthy cells and the resulting burst of radiation destroys bone metastases. Liquid radiotherapy drug Radium-223 is already available on the NHS, while the even more potent Lutetium-177 PSMA is available privately and awaiting National Institute of Health and Care Excellence (Nice) appraisal. Multimodal first strikes 'We now combine hormone drugs – and sometimes chemotherapy – immediately after diagnosis,' says Dr Wilkins. Even resistant cancers respond to this approach. Treating the original tumour with radiotherapy, even in metastatic cases, also boosts survival: 'It's as if you're silencing a mothership that coordinates the metastases,' she says. While there is no cure yet, Dr Wilkins says, these approaches are turning stage-four prostate cancer into a condition many men will live with, not die from.
Yahoo
21 hours ago
- Entertainment
- Yahoo
Ryan Seacrest Breaks Down in Tears Over Dad's Prostate Cancer Struggle: ‘No One Tells You How to Handle This'
Ryan Seacrest's father, Gary Seacrest, is navigating a difficult prostate cancer journey, the host shared in an emotional broadcast of On Air with Ryan Seacrest. The American Idol host was prompted to reveal his family's private struggle while discussing colleague Dennis Clark's 'victory story' of remission from cancer. Ryan, 50, had shared in a 2021 Instagram post that his father, who turns 81 on July 27, had been 'battling cancer for several years'— but at the time, they thought it was 'no longer detectable.' However, as he said in a July 21 broadcast of On Air with Ryan Seacrest, "It got worse and it spread.' View this post on Instagram A post shared by On Air with Ryan Seacrest (@onairwithryan) 'When this happens to somebody or someone really close to you that you love, this is a hard thing to see, because the treatments that are commonly recommended can be barbaric to the system. They can cause so much damage to your body in other ways," Ryan shared. The host also noted that Gary contracted pneumonia while undergoing chemotherapy. When Ryan was hosting American Idol's live shows last season, his sister Meredith called him with dire news: She said, ' 'Dad is in the ICU, and how fast can you get here?' ' Explaining that he's 'never really spoken about this,' Ryan said he somehow finished the episode even though 'I didn't even remember what I was saying.' Once the show wrapped, he flew to Atlanta to see his father: 'The night that I got there, the conversation they were having with [my father] about an emergency surgery was a life or death conversation, and I've never seen my strong, very smart father with the look on his face that he had — and the concern, and looking at me to help guide what decisions should be made in this moment.' Gary opted to not have surgery, Ryan said, explaining he visited his father daily in the hospital and ended up broadcasting his radio shows from his hotel room in Atlanta. 'When you see a parent suffering and when you see them going through this and you don't understand it yourself, you're just listening to all the different doctors and trying to make sense of what they're trying to suggest and do," he shared. "I didn't want to miss trying to understand who these people were that were taking care of my father.' He continued: 'He could not get up to sit. He could not eat. He could not drink water. He could not go to the bathroom. Weeks go by in ICU and finally he began to get some strength back.' Ryan noted that he wanted to help his mother, Connie, who is in remission from cancer. 'I needed her to take a break,' he said. 'When you're a kid, no one tells you how to handle this with your parents.' 'He slowly gained strength,' said Ryan, who went on to praise the 'angels' — the nurses — who looked after his father. 'The nurses are the people that nurture and care and have emotion about their patients. The nurses are the ones that are really looking after them day and night for hours, and I loved the team of nurses,' Ryan added, continuing to share that he sent them something to thank them afterward. His father was released this month and is home in Atlanta with full-time care, Ryan shared. He also revealed that he has flown back and forth from Los Angeles every weekend to visit his father, who struggled to get up out of his chair for nearly five months. 'His birthday is in a few days, and I asked him, 'What would you like for your birthday?' ' to which Ryan recalled his father replying, ' 'I just want to get out of this chair. I just want to leave this house.' ' View this post on Instagram A post shared by Ryan Seacrest (@ryanseacrest) His voice audibly broke — and Ryan took a moment to steady his emotions. He shared that the night before, 'I got the most powerful, good, happy picture from my dad and my mother, who was with him. They went to a beach to sit outside. They just went to look at the water. They can't do much, but I saw him smile. I saw my mom smile." 'I'm embarrassed,' Ryan admitted as his emotions overtook him. 'I watched them over the weekend send photos of smiling and happiness, and being together. They've been married for over 55 years. They've got each other and the pneumonia is gone, but his cancer is not.' He shared he was 'so excited and happy' for his colleague, Clark, 'When he had beaten it.' 'Cancer affects every one of us in some way, and it. And it sucks. And the treatments suck … treatments are tough. But I know he's going to get through this," Ryan continued. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
BBC News
a day ago
- Health
- BBC News
Go for your check-ups, father with prostate cancer urges men
A father-of-three has advised men not to put off routine check-ups after his own doctor's visit revealed he had stage three prostate maker Neil Maggs, 50, told BBC Radio Bristol presenter Joe Sims he could have died within 18 months had he not had prostate removal surgery in March last year."Just go and get it done – it's better to be alive," said Mr Maggs, from Fishponds in also spoke about the physical repercussions of the operation, which he said were "a massive wake-up call", affecting his mental health and sense of identity. "If your identity is, 'I'm a man, I'm a virile man', then suddenly you're having to wear a nappy at the age of 50 and can't get an erection, it becomes like a midlife crisis," he said. Symptoms of prostate cancer do not usually appear until the prostate is large enough to affect the tube that carries urine, according to the disease tends to affect over-50s, and although there is not a definitive test for it, a prostate-specific antigen (PSA) test can indicate whether cancer is the cancer is slow-growing, it can be there for decades before it is presenter Dermot Murnaghan, cyclist Chris Hoy and former US President Joe Biden are all living with prostate Maggs said he was convinced into going for a routine check-up for over-40s in January 2024, after telling a nurse he urinated later had to have a biopsy – which he described as "arguably the worst part" of his experience."The needle to numb you, it felt like someone was squeezing my balls, and punching me in the face at the same time," he said. The diagnosis came back within a week. "The moment I knew was when the nurse came out and bowed her head."I was basically near to stage four, on stage three and a half – stage four is basically fatal where you need palliative care and you will die from it," he the time his surgery was scheduled, he had "fallen into a sense of thinking, 'this could be it'"."I was kind of ready for the possibility," he said. "I wanted to be present and be with my family – it's a feeling that's kind of stayed with me." 'Moments that get you' But Mr Maggs, whose children are 13, nine and eight, said nothing could have prepared him for the mental struggle after the prostate removal surgery."For some men who have never faced their demons, it's a massive wake-up call," he said after the operation "there are moments that can get you". "I was less prepared for that," he said. "Your testosterone is less so there is a physical thing that affects your mental health."Mr Maggs said "quite a few of my mates and family have had a check-up" following his diagnosis and surgery. He now has a PSA check every two months and has been told his current levels and prognosis are both good.
Yahoo
a day ago
- Business
- Yahoo
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Approval is based on positive results from the pivotal Phase III ARANOTE trial. This broadened indication allows doctors to use darolutamide plus ADT, with or without chemotherapy (docetaxel), enabling them to better tailor treatment plans to meet the needs of patients with mHSPC. Orion's collaboration partner Bayer announced today that the European Commission has granted marketing authorization in the European Union (EU) for darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. Darolutamide, under the brand name Nubeqa®, is already approved in over 85 countries for use with ADT and docetaxel in mHSPC, and with ADT alone in non-metastatic castration-resistant prostate cancer (nmCRPC) in patients who are at high risk of developing metastatic disease. Darolutamide is developed jointly by Orion and Bayer. Prostate cancer is the second most common cancer and the fifth most common cause of cancer death in men worldwide. In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 In Europe, there were almost 474,000 estimated new cases of prostate cancer in 2022 with approximately 115,000 deaths. 2 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.3 About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is radiological progression free survival (rPFS), measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in rPFS were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans, support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile, in both mHSPC registrational studies where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as a treatment for localized prostate cancer in combination with radiotherapy. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.4,5,6 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. Contact person: Terhi Ormio, Vice President, Communications, Orion Corporation tel. +358 10 426 4646 References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: June 2025. Ferlay J et al. 2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available at: Accessed June 2025.. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
